Response to: 'COVID-19 pandemic: an opportunity to assess the utility of telemedicine in patients with rheumatic diseases' by Lopez-Medina et al

Ann Rheum Dis. 2021 Apr;80(4):e51. doi: 10.1136/annrheumdis-2020-218070. Epub 2020 Jun 5.

Authors

Emanuele Bozzalla Cassione^{1

2}, Giovanni Zanframundo^{1

2}, Alessandro Biglia^{1

2}, Veronica Codullo^{1

2}, Carlomaurizio Montecucco^{3

2}, Lorenzo Cavagna^{1

2}

Affiliations

¹ Rheumatology, Fondazione IRCCS Policlinico San Matteo, Pavia, Lombardia, Italy.
² Department of Internal Medicine and Medical Therapeutics, University of Pavia, Pavia, Lombardia, Italy.
³ Rheumatology, Fondazione IRCCS Policlinico San Matteo, Pavia, Lombardia, Italy montecucco@smatteo.pv.it.

PMID: 32503850
DOI: 10.1136/annrheumdis-2020-218070

No abstract available

Keywords: arthritis, rheumatoid; hydroxychloroquine; lupus erythematosus, systemic.

Publication types

Letter
Comment

MeSH terms

COVID-19*
Humans
Hydroxychloroquine
Lupus Erythematosus, Systemic*
Pandemics
Rheumatic Diseases* / therapy
Telemedicine*

Substances

Hydroxychloroquine